Lanova Medicines Limited

Lanova Medicines Limited Company

Lanova Medicines Development Co., Ltd.

Runsheng Li

Wentao Huang

Ying Qin Zang

Zhifang Liu

Yifan Li

Wei Cao

Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the β3-β4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the β5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Methods of treating cancer by administering an antibody-drug conjugate targeting human claudin 18.2

The present disclosure relates to anticancer compounds, including, but not limited to, antibody-drug conjugates using the same, which compounds and ACDs thereof are suitable for the treatment of cancer.

Compounds, compositions and methods

Provided are chimeric antigen receptors that include an antibody or fragment thereof having binding specificity to the human GPRC5D protein. The chimeric antigen receptors and immune cells expressing the chimeric antigen receptors are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Chimeric antigen receptors targeting GPRC5D

Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.

CEACAM5-dependent 4-1BB-agonistic bispecific antibodies

Provided are antibodies or fragment thereof having binding specificity to the human solute carrier 34 A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC) and effectively induce endocytosis. Also provided are methods and uses for treating cancers.

Anti-SLC34A2 monoclonal antibodies and uses thereof

Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1. SLC39A6 or ZIP6) protein as well as their derivatives and uses.

Antibodies targeting LIV-1 and uses thereof

Provided are antibodies and fragments thereof having binding specificity to the claudin 6 (CLDN6) protein as well as their derivatives and uses.

Antibodies and antibody-drug conjugates targeting claudin 6

Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Anti-claudin 18.2 antibodies and uses thereof

Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C—C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Anti-CCR8 monoclonal antibodies and uses thereof

Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the &#x3b2;3-&#x3b2;4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the &#x3b2;5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Antibody-drug conjugates targeting human Claudin 18.2

Provided are antibodies or fragment thereof having binding specificity to the human GPRC5D protein. The antibodies or fragment thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Growing community of inventors

Shanghai, China

Runsheng Li